H.C. Wainwright analyst Andres Maldonado raised the firm’s price target on Day One Biopharmaceuticals to $45 from $35 and keeps a Buy rating on the shares. The analyst says tovorafenib continues to maintain an approvable profile.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on DAWN:
- DAWN Rises on Promising Data in Brain Tumor Study
- Day One Biopharmaceuticals price target raised to $45 from $40 at Piper Sandler
- Day One announces top line data from pivotal Phase 2 FIREFLY-1 trial
- Day One Announces Topline Data from Pivotal Phase 2 FIREFLY-1 Trial Demonstrating Meaningful Responses with Tovorafenib (DAY101) in Recurrent or Progressive Pediatric Low-Grade Glioma
- Day One Biopharmaceuticals initiated with a Buy at H.C. Wainwright
